Literature DB >> 30052888

2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA).

Gregory Y H Lip1,2,3, Jean-Phillippe Collet4, Michael Haude5, Robert Byrne6,7, Eugene H Chung8, Laurent Fauchier9, Sigrun Halvorsen10, Dennis Lau11, Nestor Lopez-Cabanillas12, Maddalena Lettino13, Francisco Marin14, Israel Obel15, Andrea Rubboli16, Robert F Storey17, Marco Valgimigli18, Kurt Huber19.   

Abstract

In 2014, a joint consensus document dealing with the management of antithrombotic therapy in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and/or undergoing percutaneous coronary or valve interventions was published, which represented an effort of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Since publication of this document, additional data from observational cohorts, randomized controlled trials, and percutaneous interventions as well as new guidelines have been published. Moreover, new drugs and devices/interventions are also available, with an increasing evidence base. The approach to managing AF has also evolved towards a more integrated or holistic approach. In recognizing these advances since the last consensus document, EHRA, WG Thrombosis, EAPCI, and ACCA, with additional contributions from HRS, APHRS, Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA), proposed a focused update, to include the new data, with the remit of comprehensively reviewing the available evidence and publishing a focused update consensus document on the management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing percutaneous coronary or valve interventions, and providing up-to-date consensus recommendations for use in clinical practice.

Entities:  

Year:  2019        PMID: 30052888     DOI: 10.1093/europace/euy174

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  57 in total

1.  The fading role of triple therapy in patients with atrial fibrillation and acute coronary syndrome: a Bayesian network meta-analysis.

Authors:  Mohammed Osman; Babikir Kheiri; Muhammad Bilal Munir; Jason A Moreland; Sudarshan Balla; Samir Kapadia
Journal:  J Thromb Thrombolysis       Date:  2019-10       Impact factor: 2.300

2.  Dual versus triple therapy for patients with atrial fibrillation and acute coronary syndrome: a meta-analysis and trial sequential analysis of randomized controlled trials.

Authors:  Babikir Kheiri; Mohammed Osman; Ahmed Bakhit; Qais Radaideh; Ahmed Abdalla; Mahmoud Barbarawi; Yazan Zayed; Sahar Ahmed; Ghassan Bachuwa; Mustafa Hassan
Journal:  J Thromb Thrombolysis       Date:  2019-10       Impact factor: 2.300

3.  Combining antiplatelet and anticoagulant therapy in cardiovascular disease.

Authors:  Geoffrey D Barnes
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

4.  Combination of Oral Anticoagulants and Single Antiplatelets versus Triple Therapy in Nonvalvular Atrial Fibrillation and Acute Coronary Syndrome: Stroke Prevention among Asians.

Authors:  Anwar Santoso; Sunu B Raharjo
Journal:  Int J Angiol       Date:  2020-05-06

5.  To drop or not to drop the antiplatelet agent, that is the question for patients with atrial fibrillation and chronic coronary syndrome undergoing percutaneous coronary intervention.

Authors:  Yongcheol Kim; Thomas W Johnson; Young-Hoon Jeong
Journal:  Cardiol J       Date:  2020       Impact factor: 2.737

6.  Double Antithrombotic versus Triple Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome.

Authors:  Surya Dharma
Journal:  Int J Angiol       Date:  2020-03-21

Review 7.  Double or Triple Antithrombotic Treatment in Atrial Fibrillation Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention.

Authors:  Despoina-Rafailia Benetou; Charalampos Varlamos; Aikaterini Mpahara; Dimitrios Alexopoulos
Journal:  Am J Cardiovasc Drugs       Date:  2021-01       Impact factor: 3.571

8.  Mechanisms of ST-segment elevation myocardial infarction in patients with atrial fibrillation, prior stenting and long-standing chronic coronary syndrome.

Authors:  Antonio Gabriele Franchina; Dario Calderone; Paolo D'Arrigo; Salvatore Ingala; Rocco Paolo Milluzzo; Antonio Greco; Marco Spagnolo; Corrado Tamburino; Davide Capodanno
Journal:  Cardiol J       Date:  2020-01-21       Impact factor: 2.737

9.  Antithrombotic therapy for chronic coronary syndrome and atrial fibrillation: less might be more.

Authors:  Bernhard Wernly; Deepak L Bhatt; Amin Polzin; Christian Jung
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

Review 10.  Unmet Clinical Needs in Elderly Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation.

Authors:  Gianluca Botto; Pietro Ameri; Manuel Cappellari; Francesco Dentali; Nicola Ferri; Iris Parrini; Italo Porto; Alessandro Squizzato; Giuseppe Camporese
Journal:  Adv Ther       Date:  2021-05-21       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.